feed,title,long_url,short_url
Benzinga,"PharmaEngine, Inc. and Sentinel Oncology Limited Enter into an Exclusive Collaboration and License Agreement for SOL-578, a Chk1 inhibitor",https://www.benzinga.com/pressreleases/20/12/n18649488/pharmaengine-inc-and-sentinel-oncology-limited-enter-into-an-exclusive-collaboration-and-license-a,https://j.mp/3okF3zm
